We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+10.88%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.53B
AUM Growth
+$250M
Cap. Flow
+$158M
Cap. Flow %
10.38%
Top 10 Hldgs %
55.98%
Holding
48
New
9
Increased
18
Reduced
6
Closed
7

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$36.9M
2
GHDX
Genomic Health, Inc.
GHDX
+$26M
3
KERX
Keryx Biopharmaceuticals Inc
KERX
+$24.8M
4
ACHN
Achillion Pharmaceuticals
ACHN
+$23.1M
5
WW
WW International
WW
+$18.2M

Top Sells

Rank Stock Value
1
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$41.2M
2
THC icon
Tenet Healthcare
THC
+$36.2M
3
HOLX
Hologic
HOLX
+$32.3M
4
UNH icon
UnitedHealth
UNH
+$24.6M
5
ABT icon
Abbott
ABT
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 62.39%
2 Consumer Discretionary 1.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$294M 19.24%
1,500,000
+250,000
+20% +$47.5M
TEVA icon
2
Teva Pharmaceuticals
TEVA
$40.4B
$91.7M 6.01%
1,750,000
+100,000
+6% +$5.11M
ELV icon
3
Elevance Health
ELV
$81.5B
$75.3M 4.94%
700,000
-100,000
-13% -$10.3M
DGX icon
4
Quest Diagnostics
DGX
$26B
$64.6M 4.23%
1,100,000
– –
CYH icon
5
Community Health Systems
CYH
$382M
$63M 4.13%
1,679,359
+166,859
+11% +$5.55M
CNMD icon
6
CONMED
CNMD
$1.3B
$61.1M 4.01%
1,385,000
– –
VOLC
7
DELISTED
VOLCANO CORPORATION COM STK
VOLC
$55.5M 3.63%
3,150,000
+700,000
+29% +$12.7M
VTRS icon
8
Viatris
VTRS
$20.8B
$51.6M 3.38%
1,000,000
+750,000
+300% +$36.9M
HCA icon
9
HCA Healthcare
HCA
$88.4B
$50.7M 3.32%
900,000
+100,000
+13% +$5.28M
GHDX
10
DELISTED
Genomic Health, Inc.
GHDX
$47.3M 3.1%
1,725,000
+975,000
+130% +$26M
KERX
11
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$46.1M 3.02%
3,000,000
+1,750,000
+140% +$24.8M
ACHN
12
DELISTED
Achillion Pharmaceuticals
ACHN
$43.9M 2.88%
+5,800,000
New +$23.1M
MASI
13
DELISTED
Masimo
MASI
$43M 2.81%
1,820,000
+545,000
+43% +$13.5M
THC icon
14
Tenet Healthcare
THC
$22.2B
$42.2M 2.77%
900,000
-800,000
-47% -$36.2M
LH icon
15
Labcorp
LH
$25.2B
$41M 2.68%
465,600
+29,100
+7% +$2.52M
HRC
16
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$37.1M 2.43%
893,223
+293,223
+49% +$11.4M
HAE icon
17
Haemonetics
HAE
$3.88B
$35.3M 2.31%
1,000,000
-202,000
-17% -$6.75M
UAM
18
DELISTED
Universal American Corp
UAM
$34.8M 2.28%
4,178,259
– –
ARIA
19
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$31.9M 2.09%
5,000,000
+2,000,000
+67% +$13.8M
TEVA icon
20
CALL
Teva Pharmaceuticals
TEVA
$40.4B
$26.2M 1.72%
+500,000
New +$25.6M
BLUE
21
DELISTED
bluebird bio
BLUE
$25.3M 1.66%
50,713
-3,860
-7% -$1.24M
SQNM
22
DELISTED
SEQUENOM INC NEW
SQNM
$24.4M 1.6%
6,300,000
+3,388,480
+116% +$9.91M
NVAX icon
23
Novavax
NVAX
$1.21B
$21.9M 1.44%
237,500
+125,000
+111% +$11M
RVNC
24
DELISTED
Revance Therapeutics, Inc.
RVNC
$21.4M 1.4%
630,000
+330,000
+110% +$10.3M
FURX
25
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$21.2M 1.39%
200,000
+50,000
+33% +$4.9M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q2 2014 Portfolio in Review

As of Q2 2014, Camber Capital Management held 48 positions worth $1.53B, up 20% from $1.28B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Camber Capital Management deployed $158M of net new capital in Q2 2014, opening 9 new positions and adding to 18 existing holdings. Its largest new stake was Achillion Pharmaceuticals: 5,800,000 shares worth $43.9M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 71% a quarter earlier, followed by Consumer Discretionary.

On the sell side, the largest reduction was Tenet Healthcare, an estimated $36.2M trimmed.

  • Camber Capital Management's largest Q2 2014 buy was Achillion Pharmaceuticals: 5,800,000 shares worth $43.9M.
  • Camber Capital Management added most to Viatris in Q2 2014, an estimated $36.9M increase.
  • Camber Capital Management's biggest Q2 2014 reduction was Tenet Healthcare, cutting an estimated $36.2M.
  • Camber Capital Management fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q2 2014, selling an estimated $41.2M.
  • Camber Capital Management's ten largest holdings make up 56% of its $1.53B portfolio in Q2 2014.
  • Camber Capital Management opened 9 new positions and closed 7 in Q2 2014.
  • Camber Capital Management's portfolio value rose 20% quarter-over-quarter to $1.53B.

Based on Camber Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.